A Phase 3 interventional study of Brexpiprazole, OPC-34712 and Placebo Oral Tablet in Agitation Associated With, Alzheimer's Disease and Alzheimer's Type, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 85 sites in 7 countries. Open to participants aged 55 Years to 90 Years. Per ClinicalTrials.gov, last updated 2020-12-31.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Alzheimer Disease by Otsuka Holdings Co., Ltd. — 1 open to participants now, 1 under way, none of them phase 3. Alzheimer Disease · Otsuka Holdings Co., Ltd..
Among the 17 studies in Alzheimer Disease by Otsuka Holdings Co., Ltd., this one is the 3rd largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2013, is one of 13 in phase 3, and was the 8th registered.
3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →1 of the 17 studies in Alzheimer Disease by Otsuka Holdings Co., Ltd. is open now, in 1 country. Recruiting first, the newest first:
Otsuka Pharmaceutical Co., Ltd. · Sites in Japan
Ages 15+
By country, each count listing its studies:
Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.
This study: 55 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 2 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 433 is above the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.
Median enrollment 265 across the 12 interventional studies, 450 across the 3 observational. Of the 16 that completed or were terminated, 9 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
1 of the studies in Alzheimer Disease by Otsuka Holdings Co., Ltd. that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06875986Otsuka Pharmaceutical Co., Ltd.REXULTI General Use Results Survey in Patients With Hyperactivity, or Aggressive Behavior Associated With Alzheimer's Dementia | 2027-09-30 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies in Alzheimer Disease by Otsuka Holdings Co., Ltd., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To compare the efficacy of 2 fixed doses of brexpiprazole with placebo in participants with agitation associated with dementia of the Alzheimer's type.
Behavioral symptoms, such as agitation, are core features in participants with Alzheimer's disease and related dementias and develop in the majority of dementia participants. The presence of agitation in participants with Alzheimer's disease places a significant burden not only on participants and their caregivers but also on the healthcare system.
This is a trial designed to assess the safety and efficacy of brexpiprazole in the treatment of participants with agitation associated with dementia of the Alzheimer's Type. The trial consists of a continuous 12-week double-blind treatment period with a 30-day follow-up. The trial population will include male and female participants between 55 and 90 years of age (inclusive) with a diagnosis of probable Alzheimer's disease, who are residing either in an institutionalized setting or in a non-institutionalized setting where the participant is not living alone.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Matching placebo once daily
Drug: Placebo Oral Tablet
Titrate up from 0.25 milligrams (mg)/day brexpiprazole to 1 mg/day brexpiprazole
Drug: Brexpiprazole, OPC-34712
Titrate up from 0.25 mg/day brexpiprazole to 2 mg/day brexpiprazole
Drug: Brexpiprazole, OPC-34712
Once-daily, tablets
Once-daily, tablets
Change From Baseline In The Cohen-Mansfield Agitation Inventory (CMAI) Total Score After 12 Weeks Of Brexpiprazole Treatment
To compare the efficacy of 2 fixed doses (1 mg/day and 2 mg/day) of brexpiprazole with placebo in participants with agitation associated with dementia of the Alzheimer's type, by the assessment of CMAI after 12 weeks of treatment. The CMAI assesses the frequency of agitated behaviors in elderly persons, such as hitting, cursing, and restlessness. It consists of 29 items all rated on a 1 to 7 scale with 1 being the "best" rating and 7 being the "worst" rating. The minimum possible CMAI total score is 29, and the maximum possible CMAI total score is 203. A decrease in score indicates improvement in symptoms. To control the overall type I error at 0.05 level when making 2 comparisons of brexpiprazole doses versus placebo, statistical testing was carried out using a hierarchical testing procedure in the order of: 1) comparison of 2 mg/day brexpiprazole versus placebo, and 2) comparison of 1 mg/day brexpiprazole versus placebo.
Time frame: Baseline, Week 12/Early Termination (ET)
Change From Baseline In The Clinical Global Impression-Severity Of Illness (CGI-S) Score, As Related To Symptoms Of Agitation After 12 Weeks Of Brexpiprazole Treatment
To compare the efficacy of 2 fixed doses (1 mg/day and 2 mg/day) of brexpiprazole with placebo in participants with agitation associated with Alzheimer's dementia, by the assessment of CGI-S score after 12 weeks of treatment. The CGI-S was used to rate the severity of agitation. Scores were: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants. A decrease in score indicates improvement in symptoms.
Time frame: Baseline, Week 12/ET
Participants who met all the inclusion and none of the exclusion criteria were enrolled in this study. The study was conducted in 433 participants at 81 sites in 7 countries: Croatia, Germany, Serbia, Spain, Russia, Ukraine, and the United States.
| Milestone | Brexpiprazole 0.5 mg/Day | Brexpiprazole 1 mg/Day | Brexpiprazole 2 mg/Day | Placebo |
|---|---|---|---|---|
| Started | 20 | 137 | 140 | 136 |
| Completed | 13 | 121 | 122 | 121 |
| Not completed | 7 | 16 | 18 | 15 |
| Withdrew: Adverse event | 4 | 10 | 6 | 8 |
| Withdrew: Participant met withdrawal criteria | 1 | 1 | 2 | 1 |
| Withdrew: Participant withdrawn by investigator | 0 | 1 | 1 | 1 |
| Withdrew: Withdrawal by subject | 2 | 4 | 8 | 5 |
| Withdrew: Protocol deviation | 0 | 0 | 1 | 0 |
To compare the efficacy of 2 fixed doses (1 mg/day and 2 mg/day) of brexpiprazole with placebo in participants with agitation associated with dementia of the Alzheimer's type, by the assessment of CMAI after 12 weeks of treatment. The CMAI assesses the frequency of agitated behaviors in elderly persons, such as hitting, cursing, and restlessness. It consists of 29 items all rated on a 1 to 7 scale with 1 being the "best" rating and 7 being the "worst" rating. The minimum possible CMAI total score is 29, and the maximum possible CMAI total score is 203. A decrease in score indicates improvement in symptoms. To control the overall type I error at 0.05 level when making 2 comparisons of brexpiprazole doses versus placebo, statistical testing was carried out using a hierarchical testing procedure in the order of: 1) comparison of 2 mg/day brexpiprazole versus placebo, and 2) comparison of 1 mg/day brexpiprazole versus placebo.
| units on a scale | Brexpiprazole 2 mg/Day | Brexpiprazole 1 mg/Day | Placebo |
|---|---|---|---|
| Change From Baseline In The Cohen-Mansfield Agitation Inventory (CMAI) Total Score After 12 Weeks Of Brexpiprazole Treatment | -21.6 ± 1.32 | -17.6 ± 1.33 | -17.8 ± 1.34 |
To compare the efficacy of 2 fixed doses (1 mg/day and 2 mg/day) of brexpiprazole with placebo in participants with agitation associated with Alzheimer's dementia, by the assessment of CGI-S score after 12 weeks of treatment. The CGI-S was used to rate the severity of agitation. Scores were: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants. A decrease in score indicates improvement in symptoms.
| units on a scale | Brexpiprazole 2 mg/Day | Brexpiprazole 1 mg/Day | Placebo |
|---|---|---|---|
| Change From Baseline In The Clinical Global Impression-Severity Of Illness (CGI-S) Score, As Related To Symptoms Of Agitation After 12 Weeks Of Brexpiprazole Treatment | -1.29 ± 1.05 | -1.04 ± 1.12 | -1.08 ± 0.89 |
Collected over Adverse events (AEs) were collected throughout the study (Baseline to Week 12/ET).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Brexpiprazole 0.5 mg/Day | 2/20 (10%) | 5/20 (25%) | 11/20 (55%) |
| Brexpiprazole 1 mg/Day | 2/137 (1.5%) | 11/137 (8%) | 27/137 (19.7%) |
| Brexpiprazole 2 mg/Day | 1/140 (0.7%) | 13/140 (9.3%) | 43/140 (30.7%) |
| Placebo | 0/135 (0%) | 7/135 (5.2%) | 29/135 (21.5%) |
| Event | Brexpiprazole 0.5 mg/Day | Brexpiprazole 1 mg/Day | Brexpiprazole 2 mg/Day | Placebo |
|---|---|---|---|---|
| CellulitisInfections and infestations | 1/20 | 0/137 | 0/140 | 0/135 |
| EncephalitisInfections and infestations | 1/20 | 0/137 | 0/140 | 0/135 |
| FallInjury, poisoning and procedural complications | 1/20 | 0/137 | 0/140 | 0/135 |
| Humerus FractureInjury, poisoning and procedural complications | 1/20 | 0/137 | 0/140 | 0/135 |
| Haemorrhage IntracranialNervous system disorders | 1/20 | 0/137 | 0/140 | 0/135 |
| AgitationPsychiatric disorders | 1/20 | 1/137 | 1/140 | 0/135 |
| Chronic Obstructive Pulmonary DiseaseRespiratory, thoracic and mediastinal disorders | 1/20 | 0/137 | 1/140 | 0/135 |
| Urinary Tract InfectionInfections and infestations | 0/20 | 0/137 | 4/140 | 1/135 |
| Duodenal Ulcer HaemorrhageGastrointestinal disorders | 0/20 | 0/137 | 0/140 | 1/135 |
| PneumoniaInfections and infestations | 0/20 | 0/137 | 0/140 | 1/135 |
| Event | Brexpiprazole 0.5 mg/Day | Brexpiprazole 1 mg/Day | Brexpiprazole 2 mg/Day | Placebo |
|---|---|---|---|---|
| Blood Creatine Phosphokinase IncreasedInvestigations | 2/20 | 1/137 | 1/140 | 0/135 |
| HeadacheNervous system disorders | 0/20 | 12/137 | 13/140 | 11/135 |
| DizzinessNervous system disorders | 0/20 | 1/137 | 8/140 | 4/135 |
| InsomniaPsychiatric disorders | 0/20 | 7/137 | 8/140 | 6/135 |
| AnaemiaBlood and lymphatic system disorders | 1/20 | 1/137 | 2/140 | 0/135 |
| ConstipationGastrointestinal disorders | 1/20 | 1/137 | 5/140 | 1/135 |
| Salivary HypersecretionGastrointestinal disorders | 1/20 | 0/137 | 1/140 | 0/135 |
| AstheniaGeneral disorders | 1/20 | 2/137 | 3/140 | 3/135 |
| Urinary Tract InfectionInfections and infestations | 1/20 | 2/137 | 3/140 | 1/135 |
| FallInjury, poisoning and procedural complications | 1/20 | 0/137 | 3/140 | 2/135 |
| Age, Continuous(years) | Brexpiprazole 0.5 mg/Day | Brexpiprazole 1 mg/Day | Brexpiprazole 2 mg/Day | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 73.9 ± 9.1 | 73.8 ± 8.8 | 73.7 ± 8.1 | 74.1 ± 8.0 | 73.9 ± 8.3 |
| Sex: Female, Male(Participants) | Brexpiprazole 0.5 mg/Day | Brexpiprazole 1 mg/Day | Brexpiprazole 2 mg/Day | Placebo | Total |
|---|---|---|---|---|---|
| Female | 12 | 78 | 79 | 70 | 239 |
| Male | 8 | 59 | 61 | 66 | 194 |
| Race (NIH/OMB)(Participants) | Brexpiprazole 0.5 mg/Day | Brexpiprazole 1 mg/Day | Brexpiprazole 2 mg/Day | Placebo | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 1 | 2 | 1 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 2 | 5 | 5 | 12 |
| White | 20 | 134 | 133 | 130 | 417 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.
Access criteria: Otsuka will share data on an Otsuka-owned remotely accessible data sharing platform with Python and R analytical software. Research requests should be directed to clinicaltransparency@Otsuka-us.com
Ran from Jul 2013 to primary completion in Mar 2017, 44 months.
Results were first posted in Jun 2020, 3 years 3 months after primary completion. A results delay was requested in Jan 2018.
Of 75 industry-sponsored phase 3 interventional studies under Alzheimer Disease, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 61. This study's 44 months is close to that.
Counting every sponsor, half of 101 studies reached it within 47 months; a quarter within 28 and three quarters within 73.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brexpiprazole
Otsuka Pharmaceutical Development & Commercialization, Inc. →